Literature DB >> 23397414

Generic biopharmaceutical drugs: an economic and policy analysis.

Erwin A Blackstone, Joseph P Fuhr.   

Abstract

Encouraging both generic drug competition and pharmaceutical innovation is difficult, especially in the case of follow-on biologics. Can the U.S. nurture a system that seeks both lower drug prices now and new and improved medications in the future?

Year:  2007        PMID： 23397414      PMCID： PMC3564391     

Source DB:  PubMed          Journal:  Biotechnol Healthc        ISSN： 1554-169X


  7 in total

1.  The Hatch-Waxman Act: balancing competing interests or survival of the fittest?

Authors:  Kristin E Behrendt
Journal:  Food Drug Law J       Date:  2002       Impact factor: 0.619

2.  MC strategy: create competition in expanding biotech field.

Authors:  Thomas Morrow
Journal:  Manag Care       Date:  2003-09

3.  Biogenerics: Europe takes another step forward while the FDA dives for cover.

Authors:  Paul Chamberlain
Journal:  Drug Discov Today       Date:  2004-10-01       Impact factor: 7.851

4.  Biogenerics standoff.

Authors:  Stephan Herrera
Journal:  Nat Biotechnol       Date:  2004-11       Impact factor: 54.908

5.  SuperGenerics: a better alternative for biogenerics.

Authors:  Stephen A Charles
Journal:  Drug Discov Today       Date:  2005-04-15       Impact factor: 7.851

6.  Why Genzyme can charge so much for Cerezyme.

Authors:  Geeta Anand
Journal:  Wall St J (East Ed)       Date:  2005-11-16

7.  Health spending projections through 2015: changes on the horizon.

Authors:  Christine Borger; Sheila Smith; Christopher Truffer; Sean Keehan; Andrea Sisko; John Poisal; M Kent Clemens
Journal:  Health Aff (Millwood)       Date:  2006-02-22       Impact factor: 6.301
  7 in total
  1 in total

1.  Biopharmaceuticals: the economic equation.

Authors:  Erwin A Blackstone; Joseph P Fuhr
Journal:  Biotechnol Healthc       Date:  2007-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.